The Xa factor: not looking so promising for Pfizer and Bristol - Bristol-Myers Squibb and Pfizer's apixaban blood clot preventer raised rates of bleeding in a 6-month study but showed some encouraging …
Pharma News 8_1
Who needs exercise? Maybe we can get the benefits in a pill! - That dream, cherished by millions of sedentary couch potatoes, just got a little bit closer. Today, researchers are reporting that an …
Pharma News 6_6
Fresh news from the ADA (American Diabetes Association): Takeda's alogliptin shows impressive results - Takeda Pharmaceutical Co Ltd's experimental diabetes drug alogliptin significantly lowers …
Pharma News 3_29
Breaking news from the ACC: Vytorin/Zetia gets panned - shows no benefit on the primary endpoint, though effective in reducing some markers. Doctors now wary and skeptical. Merck and Schering-Plough …
Pharma News 3_22
Cephalon's Treanda approved for leukemia: Cephalon Inc. received clearance from regulators yesterday to begin selling Treanda as a treatment for a rare form of leukemia. The medicine will be a new …
Cholesterol – good, bad, and indifferent
What a week it was for cholesterol! It was Lipidemia Rollercoaster - here's a summary. First, the kerfuffle with Vytorin. As you have probably heard, Merck and Schering-Plough have been roundly …
Continue Reading about Cholesterol – good, bad, and indifferent →